ACI: Healthcare stocks on the mend

American Century Investments portfolio manager Nathan Rawlins and senior investment director Mike Rode on a sector positioned for a potential turnaround

Stethoscope and pen in doctor robe pocket. Concept Of The Global Healthcare, Medicine And Insurance
3–4m

By American Century Investments portfolio manager Nathan Rawlins and senior investment director Mike Rode

Imagine the stockmarket as a waiting room. In one chair sits artificial intelligence stocks — like a robust, energetic patient who’s eager to get moving but needs to avoid burnout.

In the next chair are healthcare stocks — like a patient recovering from an illness, regaining strength and showing promising signs of a full recovery with the right support.

Throughout much of 2025, healthcare stocks experienced limited growth due to regulatory uncertainty, tariffs and other factors. However, many of the challenges facing healthcare in 2025 are exaggerated, unlikely to materialise or have already been reflected in current stock prices.

Indeed, healthcare stocks began to show signs of improvement in early August. We also think certain pockets of the healthcare sector have strong fundamentals that could offer the benefit of diversification if the market starts to broaden.

Challenges

A key reason healthcare stocks have struggled in 2025 is the market environment, which has benefitted higher-risk and expensive sectors like technology. However, this environment may be shifting, opening doors for healthcare to regain its footing.

Challenges faced by specific sectors, along with the risk of tariffs, have negatively impacted the performance of some healthcare stocks. Investors should keep in mind that policy developments and regulatory changes are often temporary; while they may influence short-term sentiment, they rarely affect the long-term fundamentals of companies.

Managed care companies, which administer private health insurance plans and government programmes such as Medicare and Medicaid, have posted terrible earnings, dragging down the broader healthcare sector. Much of this stems from a cycle of mispricing their premiums. Still, as these companies adjust, we expect improved pricing strategies to help restore their profitability.

Pharmaceutical companies have been under pressure from various sources. Early in the year, Robert F. Kennedy Jr’s appointment as the secretary of the Department of Health and Human Services affected their stocks. Kennedy has openly expressed his desire to lower drug prices and his concerns that some pharmaceutical products may be harmful.

Tariff announcements, one as high as 250%, have also pressured pharmaceutical stocks. Like Trump’s other proposed tariffs, the one targeting pharmaceuticals was fluid. Under the US framework trade agreement with the EU, tariff rates on pharmaceuticals were capped at 15%, significantly lower than the original proposal.

Along similar lines, investors believed that tariffs would significantly impact medical device companies. But the sector’s ability to adapt, with companies continuing to leverage innovation and operational adjustments to weather challenges and position for growth.

Strong corners of the healthcare sector

Other healthcare industries have persisted through what’s been an otherwise tough year for the sector. Their resilience demonstrates the diversity within healthcare, and we think select opportunities remain compelling for forward-looking investors.

Contract research organisations (CROs), which manage data and clinical trials for drugmakers, have seen improvement after a rough first half of 2025.

CROs have reported an uptick in activity from biopharma and smaller biotechnology companies that delayed projects earlier in the year. Tariff uncertainty remains a concern for companies, but the second half of 2025 is expected to be better than the first half.

Similarly, clinical laboratories have seen gains in demand and volumes. Dental products companies, which have faced hurdles with utilisation trends and interest rates, are also seeing a bounce.

The continued progress in these subsectors underlines how adaptability and focused execution can help companies overcome adversity, making them potentially well-positioned for further gains as sector headwinds abate.

The healthcare sector’s challenges have led to low valuations, as many growth investors have exited in favour of the booming fortunes of other sectors like technology.

However, healthcare’s low prices position the sector for a potential turnaround, regardless of whether the bull market continues or dissipates. Despite the challenges posed by policy uncertainty and new regulations, there are signs of life for investors in the healthcare sector.